BOSTON, June 02, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that on June 1, 2022, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 27,100 shares of its common stock to three new employees, consisting of inducement stock options to purchase an aggregate of 18,065 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 9,035 shares of its common stock. These inducement stock options and inducement RSUs are subject to the terms of the Rhythm Pharmaceuticals, Inc. 2022 Employment Inducement Plan (the "Inducement Plan").
hello world
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
